What are the recommendations for antiplatelet and anticoagulant therapy for percutaneous coronary intervention?
The American College of Cardiology/American Heart Association (ACC/AHA) Task Force recommends using a combination of aspirin and a P2Y12 inhibitor (e.g., clopidogrel or ticagrelor) for at least 12 months after percutaneous coronary intervention (PCI). Additionally, they suggest that a glycoprotein IIb/IIIa inhibitor may be used if the patient is undergoing a high-risk procedure, such as those involving a high-risk lesion or a bifurcation lesion. Lastly, they suggest that an anticoagulant such as a direct thrombin inhibitor (e.g., argatroban) should be used if the patient has a contraindication to a P2Y12 inhibitor.  